GH and IGF-1 testing: what baseline levels tell clinicians before starting secretagogues

A blood test before starting a growth hormone protocol isn’t optional — it’s the foundation for doing it right.

TL;DR

• IGF-1 is the downstream marker clinicians use to assess growth hormone (GH) axis function — and to monitor secretagogue therapy.
• A baseline before starting shows where you are, which guides whether a secretagogue protocol is appropriate and at what intensity.
• Testing at 8–12 weeks after starting lets your clinician confirm the protocol is working and adjust accordingly.

What it is

IGF-1 (insulin-like growth factor 1 — a hormone produced mainly in the liver in response to growth hormone signals) is the primary biomarker used to assess GH axis activity. Think of the relationship like a relay race: the brain’s hypothalamus fires a starting signal (GHRH — growth hormone-releasing hormone), the pituitary gland responds by releasing GH (growth hormone), and GH then signals the liver to produce IGF-1.

Because GH itself is released in pulses and hard to catch in a single blood draw, IGF-1 — which stays stable throughout the day — is the practical proxy for GH activity.

Why baseline matters

Growth hormone secretagogues (in plain English: peptides that stimulate the pituitary gland to release its own GH — like CJC-1295, ipamorelin, and sermorelin) work by amplifying the GHRH signal. If a patient already has a robust GH axis, a secretagogue may provide modest additional benefit. If the axis is genuinely suppressed — IGF-1 below the age-appropriate range — there is more clinical rationale for intervention.

A baseline IGF-1 also prevents a common error: starting a secretagogue protocol in someone whose GH axis is already performing well, which carries a small but real risk of pushing IGF-1 into supraphysiologic (higher than the natural healthy range) territory.

Who asks about it

People who are interested in starting a growth hormone peptide protocol and want to understand what pre-protocol testing looks like, or who have already been prescribed a secretagogue and want to know what the lab monitoring is for.

What the research says

The Endocrine Society’s clinical practice guidelines for GH deficiency emphasize that IGF-1 measurement is the cornerstone of both diagnosis and monitoring. Studies on CJC-1295/ipamorelin and sermorelin in healthy older adults consistently use IGF-1 as the primary efficacy endpoint — confirming that a protocol is stimulating the GH axis appropriately. Supra-normal IGF-1 levels (above the age-adjusted upper limit of normal) have been associated with increased insulin resistance and other adverse signals in long-term observational studies — making the “aim for the middle of the reference range” guidance clinically meaningful.

What to know before considering it

IGF-1 interpretation requires clinical context. The number alone doesn’t tell you what to do — age, sex, symptoms, and other biomarkers all factor in. A result in the lower third of the normal range in a 52-year-old experiencing fatigue, reduced muscle mass, and poor sleep is a different clinical picture from the same number in an asymptomatic 35-year-old. See our IGF-1 reference ranges overview for more detail.

The Halftime POV

We don’t prescribe secretagogues without a baseline IGF-1. It’s not a formality — it’s the data that makes the protocol rational. A clinician who skips the baseline is flying blind on whether the protocol is doing anything useful and whether it’s doing too much.

Related reading:

• What IGF-1 measures and why it matters
• Baseline blood panel before starting a peptide protocol
• IGF-1 reference ranges: what optimal actually means

FAQ

Q: Why is IGF-1 tested before starting growth hormone secretagogues? A: It establishes where your GH axis is starting from. This guides whether a secretagogue is clinically indicated, what dose to start at, and what range to target. Without a baseline, there’s no reference point for monitoring.

Q: What is a normal IGF-1 level? A: IGF-1 ranges are age- and sex-adjusted. Midlife adults typically aim for the mid-range of the age-appropriate reference interval — not maximum. Your lab’s reference range, interpreted by your clinician in context, is the guide.

Q: How often should IGF-1 be monitored on a secretagogue protocol? A: Typically at 8–12 weeks after starting or adjusting the protocol, then every 3–6 months once stable. The goal is an age-appropriate response — not maximized levels.

Disclaimer

This article is educational and is not medical advice. Compounded medications are not FDA-approved. Clinical outcomes depend on individual factors and require physician evaluation. Results vary. Halftime Health is launching soon — join the waitlist to get updates.

Get updates

Halftime Health is launching soon. We’ll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we’ll email you when we’re live.

Sources

• Molitch ME et al., “Evaluation and Treatment of Adult Growth Hormone Deficiency,” JCEM, 2011
• NIH MedlinePlus — IGF-1 Test

This article discusses compounds that are currently under FDA Category 2 review (see our FDA categorization explainer). These compounds are not currently part of Halftime Health’s published protocol catalog. This article is provided for educational purposes only and does not constitute medical advice or an offer to sell.